Huang, S., Lin, C., Lin, H., Yao, M., Tang, J., Wu, S., . . . Tien, H. (2014). Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Springer Berlin Heidelberg.
Chicago Stili AlıntıHuang, Shang-Yi, et al. Expression of Cereblon Protein Assessed By Immunohistochemicalstaining in Myeloma Cells Is Associated With Superior Response of Thalidomide- and Lenalidomide-based Treatment, but Not Bortezomib-based Treatment, in Patients With Multiple Myeloma. Springer Berlin Heidelberg, 2014.
MLA AlıntıHuang, Shang-Yi, et al. Expression of Cereblon Protein Assessed By Immunohistochemicalstaining in Myeloma Cells Is Associated With Superior Response of Thalidomide- and Lenalidomide-based Treatment, but Not Bortezomib-based Treatment, in Patients With Multiple Myeloma. Springer Berlin Heidelberg, 2014.